GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (FRA:FP1) » Definitions » EV-to-EBITDA

Salarius Pharmaceuticals (FRA:FP1) EV-to-EBITDA : 0.23 (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Salarius Pharmaceuticals's enterprise value is €-1.94 Mil. Salarius Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-8.55 Mil. Therefore, Salarius Pharmaceuticals's EV-to-EBITDA for today is 0.23.

The historical rank and industry rank for Salarius Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

FRA:FP1' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.18   Med: -0.13   Max: 0.99
Current: 0.23

During the past 10 years, the highest EV-to-EBITDA of Salarius Pharmaceuticals was 0.99. The lowest was -7.18. And the median was -0.13.

FRA:FP1's EV-to-EBITDA is ranked better than
88.64% of 449 companies
in the Biotechnology industry
Industry Median: 9.2 vs FRA:FP1: 0.23

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Salarius Pharmaceuticals's stock price is €0.382. Salarius Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.306. Therefore, Salarius Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Salarius Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Salarius Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals EV-to-EBITDA Chart

Salarius Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.70 -1.45 0.53 0.38 0.24

Salarius Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.30 0.25 0.24 0.21

Competitive Comparison of Salarius Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Salarius Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's EV-to-EBITDA falls into.



Salarius Pharmaceuticals EV-to-EBITDA Calculation

Salarius Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-1.935/-8.55
=0.23

Salarius Pharmaceuticals's current Enterprise Value is €-1.94 Mil.
Salarius Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Salarius Pharmaceuticals  (FRA:FP1) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Salarius Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.382/-2.306
=At Loss

Salarius Pharmaceuticals's share price for today is €0.382.
Salarius Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.306.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Salarius Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals (FRA:FP1) Business Description

Traded in Other Exchanges
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Salarius Pharmaceuticals (FRA:FP1) Headlines

No Headlines